This year, our research priorities include:
▶ Advancing prostate cancer research
We are supporting research into highly targeted radiation techniques designed to delay the need for more aggressive treatments, while reducing side effects and improving quality of life for patients with advanced prostate cancer.
▶ Expanding theranostics
With the opening of Icon’s new specialist centre in Western Australia, we are well positioned to support new clinical trials in theranostics – a promising area of oncology which combines advanced imaging and targeted therapy to deliver more personalised treatment options.
▶ Strengthening investigator-led radiation trials
Radiation therapy remains central to most cancer treatments but receives limited commercial funding for clinical trials. Through Icon’s national radiation oncology network, our clinician-led trials explore innovative ways to combine radiation with other therapies across multiple cancer types, helping to refine and improve treatment approaches.
▶ Investing in cellular therapy and blood cancer research
Building on Icon’s longstanding expertise in stem cell therapy, ICF is investing in the next generation of cellular therapies and clinical trials for blood cancers by expanding infrastructure and supporting more clinical positions. This approach strengthens our research capabilities while providing additional care to our patients.
